Targeting ATR and PI3Kα Pathways Promotes Ferroptosis in PIK3CA-Wildtype Platinum-Resistant Endometrial Cancer
Cancers · 25.03.2026 · 18 (7) · 1064
DOI: 10.3390/cancers18071064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.03.2026. Verfasst von Chi-Ting Shih und 3 weiteren Autor:innen. Beteiligte Einrichtung: Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 208…. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Intramural Research Program of the Center for CCR, NCI, NIH.
Abstract (Originalsprache)
Background/Objectives: Platinum resistance in endometrial cancer (EC) remains a significant therapeutic challenge, as tumors frequently bypass apoptotic cell death. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, offers an alternative mechanism to target apoptosis-resistant cancers. This study evaluated whether combined inhibition of ATR and PI3Kα could induce cell death in platinum-resistant EC through apoptotic or ferroptotic pathways.
Methods
A panel of EC cell lines, including patient-derived models with varying PIK3CA mutation status and platinum sensitivity, was treated with camonsertib (ATR inhibitor) and inavolisib (PI3Kα inhibitor). Cell death mechanisms were assessed through DNA damage indicators (γH2AX, comet assay, DNA fiber analysis), apoptosis markers (Annexin V, cleaved PARP, cleaved caspase 3), and ferroptosis markers (FerroOrange, xCT expression, redox homeostasis).
Results
While monotherapies showed limited activity, dual ATR and PI3Kα inhibition produced additive/synergistic cytotoxicity across all EC cell lines, independent of platinum sensitivity or microsatellite stability status. Mechanistically, the treatment induced genotype-specific cell death: PIK3CA-mutant cells underwent apoptosis driven by catastrophic DNA damage accumulation, whereas PIK3CA-wildtype cells exhibited predominantly ferroptosis characterized by xCT downregulation and redox disruption.
Conclusions
Our findings establish dual ATR and PI3Kα inhibition as a genotype-informed therapeutic strategy for platinum-resistant EC. PIK3CA mutation status may influence the mode of cell death, supporting its use as a predictive biomarker for patient stratification in future clinical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- GlaxoSmithKline (GSK), Collegeville, PA 19426, USA.
ORCID-Profile: Tzu-Ting Huang
Förderung
- NCI NIH HHS
- Intramural Research Program of the Center for CCR, NCI, NIH
Zitieren
APA
Shih, C. T., Ibanez, K. R., Lee, J. M., & Huang, T. T. (2026). Targeting ATR and PI3Kα Pathways Promotes Ferroptosis in PIK3CA-Wildtype Platinum-Resistant Endometrial Cancer. Cancers, 18(7), 1064. https://doi.org/10.3390/cancers18071064
Vancouver
Shih CT, Ibanez KR, Lee JM, Huang TT. Targeting ATR and PI3Kα Pathways Promotes Ferroptosis in PIK3CA-Wildtype Platinum-Resistant Endometrial Cancer. Cancers. 2026;18(7):1064. doi:10.3390/cancers18071064
BibTeX
@article{Shih2026,
author = {Shih, Chi-Ting and Ibanez, Kristen R and Lee, Jung-Min and Huang, Tzu-Ting},
title = {Targeting ATR and PI3Kα Pathways Promotes Ferroptosis in PIK3CA-Wildtype Platinum-Resistant Endometrial Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1064},
doi = {10.3390/cancers18071064}
}
EUVIMED